Browsing Tag
Alzheimer’s Disease
56 posts
Schroders Capital invests in Neurona Therapeutics to advance neural cell therapies
In a significant development for the life sciences sector, Schroders Capital Global Innovation Trust plc has announced a…
Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s…
Halozyme Therapeutics announces licensing deal with Acumen Pharmaceuticals for Alzheimer’s therapy advancement
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership…
Corium, Lotus Pharmaceutical seal deal for Alzheimer’s drug ADLARITY in Asia
Corium, a biopharmaceutical frontrunner in the neuroscience arena, and Lotus Pharmaceutical, a global pharmaceutical powerhouse, have declared a…
Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023…
Quanterix launches diagnostic test aiding early Alzheimer’s detection
Quanterix, a biomarker detection firm powering scientific research and breakthrough diagnostics, has introduced LucentAD, a new test designed…
Roche, Lilly team up to develop EAPP blood test for Alzheimer’s disease
Roche is teaming up with Eli Lilly and Company (Lilly) to support the development of its Elecsys Amyloid…
Eisai, Biogen secure Leqembi FDA accelerated approval for Alzheimer’s disease
Eisai and Biogen have secured the approval of the US Food and Drug Administration (FDA) for their jointly…
Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients
Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer’s…
Suven Life Sciences to launch phase 3 clinical trial for Masupirdine
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine)…